AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02618837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Downstream strategy
Description: At diagnosis:~Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel~Pre-procedure:~Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.~In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor~At the time of PCI, the loading doses required (according to randomization):~* Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months~* Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel\* daily for at least 12 months~  * If subject is >75 years old or \<60 kg, daily dose of prasugrel should be 5mg
Study NCT02825719 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Placebo pills will be prescribed
Study NCT02825719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous sulphate
Description: Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
Study NCT02825719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Description: Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
Study NCT02825719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
Study NCT02825719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
Study NCT06057259 — intervention group
Intervention type: DEVICE
Intervention: Joint position sense measurement
Description: The participants' wrist joint position sense was evaluated.
Study NCT02618837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upstream strategy
Description: At the time of diagnosis:~Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.~Pre-procedure:~All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.~All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF).
Study NCT03648125 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: with artificial occlusal disturbance
Description: A silicon artificial occlusal disturbance is made from a mould of the rowers mouth and placed in the mouth during the training session.~With artificial occlusal disturbance : Maximal Intercuspal Occlusion (MIO) with silicone splint increases the vertical dimension of occlusion of 1, 2 and 4 mm.
Study NCT03648125 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: without artificial occlusal disturbance
Description: The training session is performed without occlusal disturbance
Study NCT02783222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: comparison of different dosages of drug
Study NCT02783222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: comparison of different dosages of drug
Study NCT02202434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: Procedure: Transcatheter aortic valve replacement (TAVR)
Study NCT02202434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoreValve/Evolut R Transcatheter Aortic Valve Replacement System
Description: Procedure: Transcatheter aortic valve replacement (TAVR)
Study NCT02202434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOTUS Edge Valve System
Description: Procedure: Transcatheter aortic valve replacement (TAVR)
Study NCT00638196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linoleic Acid/Oleic Acid
Description: Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
Study NCT04374396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real ultrasound-guided single shot erector spinae plane block (ESP B)
Description: ESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~After negative aspiration, 0.3 mL/kg- of bupivacaine 0.25% will be injected confirming correct position by visualizing the solution lifting the ESM off the transverse process .Spread of LA between the L1 and L4 transverse processes will be thereafter visually tracked with the transducer. In the control group, no local anesthetics will be injected.
Study NCT04374396 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound-guided single shot erector spinae plane block (ESP B)
Description: EESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~No local anesthetics will be injected
Study NCT02090335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In SHAPE
Description: In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
Study NCT02090335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness Club Membership
Description: Fitness club membership with education in using the exercise equipment.
Study NCT02090335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness Club Membership
Description: Fitness club membership with education in using the exercise equipment.
Study NCT01358838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ablative 10600 nm fractional laser therapy
Description: Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.~Half of the scar, or one of two comparable scars, will receive no treatment at all.
Study NCT02757924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with prebiotics
Description: Sole source nutrition
Study NCT06243107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-chi
Description: Participants will each receive a Tai Chi manual and have access to an instructional audio-visual material via a QR code. The instructional material is tailored specifically for cancer patients. Participants will receive individualized guidance and instructions from the researcher (YH) until they have completed all the executions on the checklist to the required standards.
Study NCT02424409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2: Intervention
Description: 1. The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.~   A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter~2. A written action plan with formalized recommendations for the patient~3. A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.~   The ED doctor at discharge will explain all these documents orally~4. Recommendations for an early contact with the general practitioner;~5. Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner.
Study NCT02424409 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1: Control
Description: patients without discharge protocol
Study NCT04889235 — intervention group
Intervention type: PROCEDURE
Intervention: Major liver resection
Description: All patients undergo Major hepatic resection, differences between sarcopenia and no-sarcopenia groups will be observed
Study NCT04490135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Description: As described above
Study NCT04632901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VA assessment
Description: The VA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 2.58 times the SD of the reading time of these lines.~In clinical practice, the VA is the common parameter of VA adding a tolerant time limit to clearly determine the end of the test.
Study NCT04632901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CVA assessment
Description: The CVA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 1.96 times the SD of the reading time of these lines.~In clinical practice, the CVA is the minimum VA that can be read in maximal speed.
Study NCT00238381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 5 cm colon-J-pouch
Description: 5 cm colon-J-pouch with/without temporary protective ileostomy
Study NCT00238381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: side-to-end anastomosis
Description: side-to-end anastomosis with/without temporary protective ileostomy
Study NCT00238381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: straight coloanal anastomosis
Description: straight coloanal anastomosis with/without temporary protective ileostomy
Study NCT02646215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold inspiratory muscle training
Description: Inspiratory muscle training
Study NCT00110253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Description: S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
Study NCT00844740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
Study NCT01108458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: iv, 840 mg, 420 mg
Study NCT01866657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoconstrictor Agents
Description: cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
Study NCT01866657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head/neck repositioning
Description: Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
Study NCT01866657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase ETCO2
Description: Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
Study NCT01866657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluid bolus
Description: Administer IV fluids to increase preload and cardiac output
Study NCT01866657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional anesthesia
Description: By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
Study NCT01866657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Description: By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
Study NCT01866657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increase FiO2
Description: Increase FiO2 to improve oxygen delivery to tissue
Study NCT01046279 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
Study NCT00552981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inhalation of warm air in a Finnish sauna
Description: three times on three following days, each 2-3 minutes
Study NCT00552981 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: inhalation of ambient air in a Finnish sauna
Description: three times on three following days, each 2-3 minutes
Study NCT03194750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Share ultrasound measurement of IVC collapsibility to Nephrology Attending
Description: Nephrology attending will be provided with the respiratory variability of IVC diameter as a percent, in addition to a predefined cutoff for responsiveness to volume resuscitation of \< 12%. The information will be provided before rounds and before the attending sets the fluid removal goals on dialysis for that day.
Study NCT03194750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending
Description: Respiratory variability of IVC diameter will be measured, but the measurement result will not be shared with the treating team.
Study NCT01108458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: PO, 150 mg
Study NCT01716143 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: radiofrequency catheter ablation
Study NCT01402596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0,4 mg per kg - intranasal midazolam - once
Study NCT01402596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloral Hydrate
Description: 50 mg per kg, rectal
Study NCT00718822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen concentration in the culture atmosphere
Study NCT02556437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HyQvia
Description: Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
Study NCT02556437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcuvia
Description: Human immunoglobulin 16% for subcutaneous injection
Study NCT02287350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium oral solution
Description: Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
Study NCT01010295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline (tetracycline)
Description: doxycycline 100 mg twice daily for 3 weeks
Study NCT01597375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
Study NCT01597375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel Oral Tablet
Description: Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
Study NCT03285568 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Observe patients receiving palbociclib for dose adjustment and lab monitoring
Study NCT00615862 — intervention group
Intervention type: OTHER
Intervention: Observational study; no interventions
Description: Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
Study NCT00650117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
Description: single application
Study NCT00650117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Scotch Duct Tape (3M)
Description: single application
Study NCT00650117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
Description: single application
Study NCT03594903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video intervention (therapy expectation violation)
Description: The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).
Study NCT03594903 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: video intervention (symptoms+ expectation)
Description: Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
Study NCT01582789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: enfilcon A daily wear soft contact lens
Study NCT01582789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: senofilcon A daily wear soft contact lens
Study NCT03383796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three dimensional laparoscopic resection for pCCA
Description: Three dimensional laparoscopic resection for pCCA
Study NCT03383796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open resection for pCCA
Description: Open resection for pCCA
Study NCT01784432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy and training
Study NCT01784432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Study NCT04591535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Study NCT01478711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support Tool
Description: A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
Study NCT02790073 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SNF472
Description: SNF472 for calciphylaxis
Study NCT01811979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral sucrose solution
Description: Oral sucrose solution plus topical anesthetics
Study NCT01811979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Steril water
Description: steril water plus topical anesthetics